Systemic treatments for hepatocellular carcinoma: challenges and future perspectives

Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Hepat Oncol
Main Authors: Tovoli, Francesco, Negrini, Giulia, Benevento, Francesca, Faggiano, Chiara, Goio, Elisabetta, Granito, Alessandro
Format: Artigo
Jezik:Inglês
Izdano: Future Medicine Ltd 2018
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168042/
https://ncbi.nlm.nih.gov/pubmed/30302192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2017-0020
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki